logo

For the Inventor, By the Inventor

Gyeonggi-do, South Korea

Crystalgenomics, Inc.


USPTO Granted Patents = 10

% Expired Patents = 20.0



Forward Citations = 32

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Joong Myung Cho (9 out of 14 patents)

silverMedal Seonggu Ro (6 out of 7 patents)

bronzeMedal Yong Rae Hong (3 out of 3 patents)

4.  Jeong Eun Na (3 out of 7 patents)

5.  Im Sook Min (3 out of 3 patents)

6.  Hyun Ju Cha (3 out of 3 patents)

7.  Sool Ki Kwon (3 out of 3 patents)

8.  Dongkyu Shin (2 out of 8 patents)

9.  Seong Gu Ro (2 out of 7 patents)

10.  Jae Pyoung Cho (2 out of 2 patents)

11.  Young Lan Hyun (2 out of 2 patents)

12.  Young Ho Jeon (1 out of 2 patents)

13.  Jae-yeon Park (1 out of 3 patents)

14.  Takayuki Irie (1 out of 6 patents)

15.  Masaaki Sawa (1 out of 18 patents)


10 patents:

1. 11655207 - Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same (2023-05-23),
2. 11602517 - Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of pain (2023-03-14),
3. 11230539 - 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same (2022-01-25),
4. 10604508 - 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same (2020-03-31),
5. 10413520 - Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability (2019-09-17),
6. 9758508 - 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same (2017-09-12),
7. 8119812 - Thiazolidinone derivative (2012-02-21),
8. 8053435 - Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same (2011-11-08),
9. 7973060 - Fab I inhibitor and process for preparing same (2011-07-05),
10. 7179832 - Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof (2007-02-20),
Company Overview
Crystalgenomics, Inc. is a biotechnology company based in Gyeonggi-do, South Korea, specializing in the development of innovative therapeutics and diagnostics. The company focuses on harnessing advanced biopharmaceutical technologies to address unmet medical needs, particularly in the fields of oncology and infectious diseases. With a commitment to research and development, Crystalgenomics aims to create effective solutions that enhance patient outcomes and contribute to the advancement of healthcare globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

10 Patents

#72 in Gyeonggi-do

#1,090 in South Korea

#56,047 in the World

Gyeonggi-do, KR
Gyeonggi-do, South Korea

Crystalgenomics, Inc.

Forward Citations = 32

34 inventors:

goldMedal Joong Myung Cho (9 out of 14 patents)

silverMedal Seonggu Ro (6 out of 7 patents)

bronzeMedal Yong Rae Hong (3 out of 3 patents)

4.  Jeong Eun Na (3 out of 7 patents)

5.  Im Sook Min (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Crystalgenomics, Inc.. Retrieved from https://idiyas.com/company/crystalgenomics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…